Last updated on October 2016

Evaluate Efficacy and Safety of Recombinant Factor VIII rFVIII Treatment of Severe or Moderately Severe Hemophilia A


Brief description of study

Efficacy, Safety and Pharmacokinetics Study of a rFVIII in Chinese subjects with Hemophilia A.To assess efficacy and safety of rFVIII administered as treatment and as on-demand therapy in adult and adolescent (12-65 years) patients with severe or moderately severe Hemophilia A. To determine the pharmacokinetic (PK) parameters of rFVIII.

Clinical Study Identifier: NCT02930317

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Zimin Sun, Doctor

Anhui provincial hospital
Hefei, China
  Connect »

Xuefeng Wang, Doctor

Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
  Connect »

Linhua Yang, Doctor

Second hospital of Shanxi Medical University
Taiyuan, China
  Connect »

Lei Zhang, Doctor

Blood Diseases Hospital, Chinese Academy of Medical Science (Institute of Hematology)
Tianjin, China
  Connect »